Summit Details

Science, Regulation and Public Health

Smoking is the biggest single cause of preventable death in the developed world with almost 1 billion users worldwide. The devastating effect of long-term smoking cannot be underestimated, with approximately half of all lifetime smokers dying from smoking related diseases and many more suffering a compromised quality of life.  Despite decades of successful tobacco control efforts, we are still a long way from ending the smoking epidemic. The emergence of e-cigarettes has created one of the most controversial and contentious public health issues of a generation, with divisions appearing within longstanding professional alliances in both Tobacco Control and Public Health communities, despite a continued shared goal of protecting public health and ending the smoking epidemic.

The E-Cigarette Summit provides a  neutral platform to explore the available peer reviewed evidence and debate the issues that are dividing scientists, health professionals and policy makers alike. So, are-cigarettes a valuable harm reduction strategy or a tacit U-turn on decades of effective tobacco control efforts? Whichever side of the debate you fall on, this is likely to be one of the most significant public health issues for a generation.

The last 12 months have again seen momentous change in the US tobacco control and legal and regulatory landscape. The tragic EVALI outbreak, which in the minds of many still appears to have been related to nicotine-containing e-cigarettes despite the CDC’s identifying of Vitamin E acetate in THC-containing vapor products as a “primary cause,” triggered a wave of hostile government action and tobacco control activism directed at the e-cigarette industry. The EVALI crisis developed concurrently with the release of the 2019 NYTS data, which reflected another dramatic rise in past 30-day e-cigarette use by both high school and middle school youth. Both events appeared to play a role in the President’s surprise September 11 announcement of a decision to remove all flavored e-cigarette products from the marketplace. Though that announcement was partially moderated in FDA’s January 2 guidance that directed the removal of flavored “cartridge based” products only, there is increased uncertainty around the future of flavored e-cigarettes in the U.S. Now, less than 10 days after this year’s Summit, all U.S. e-cigarette products that seek to remain on the market will be required to enter the premarket tobacco product application (PMTA) process with the FDA – a process that could lead to the removal from the market of a significant number of current products, while potentially answering critical questions regarding product safety and the role of flavors for those products that are able to successfully obtain a PMTA.

As we look ahead to the next 12 months, it remains to be seen how the long-awaited PMTA deadline will impact on the industry. Critical questions include whether FDA product review will provide a measure of stability to the marketplace and whether it will improve the tenor of the U.S. tobacco control conversation. The 2020 NYTS numbers, due out this summer, will be examined closely and could again significantly impact legal and regulatory policymaking. This year’s E-Cigarette Summit USA therefore comes on the eve of a historical transition for the US e-cigarette industry. As always, the Summit looks to provide an evidence based environment that encourages open and respectful dialogue on the key science and current public health topics, with a single aim of reducing smoking related death and disease.

2020 Key Topics included:

• Tobacco Control, Harm Reduction and Science – Maintaining integrity
• What are the likely impacts of the PMTA and new regulations
• Latest youth and adult data
• The emerging interaction between cannabis, vaping and smoking in young people
• What lessons can be learned from the tragic EVALI cases
• The differing toxicology of nicotine and THC vapour
• “Devaluing” combusted products and the continuum of risk for nicotine containing products
• What does the evidence say on nicotine harm and the developing brain
• How can we reach a sustainable consensus on tobacco harm reduction and tobacco control
• Has protecting youth overshadowed the opportunity to help smokers
• PMTA and MRTP regulation – what this will mean for public health, industry and consumers
• U.S. Tobacco Control Lessons Learned from the Intersection of Wall Street and Washington
• Is Vaping reducing smoking
• How to communicate harm to the public

2020 Confirmed Speakers/Panel Presenters

Prof Jasjit S. Ahluwalia

Professor, Behavioural and Social Sciences & Internal Medicine

Brown University, School of Public Health & Alpert School of Medicine

Deborah Arnott

Chief Executive

Action on Smoking and Health (UK)

Clive Bates


Counterfactual Consulting Ltd

Kathleen Crosby

Director, Office of Health Communication & Education

FDA Center for Tobacco Products

Dr Mike Cummings

Professor, Dep't Psychiatry & Behavioural Sciences

Medical University of South Carolina

Dr Amy L. Fairchild

Dean College of Public Health

The Ohio State University

David Graham

Chief Impact Officer


Prof Peter Hajek

Professor of Clinical Psychology

Queen Mary University of London

Prof Dorothy Hatsukami

Professor, Department of Psychiatry

Associate Director of Cancer Prevention and Control for the Masonic Cancer Center, University of Minnesota

Matthew R. Holman

Director, Office of Science (OS),Center for Tobacco Products (CTP)

U.S. Food and Drug Administration

Andy Hyland

Scientific Principal Investigator

PATH Study Roswell Park Comprehensive Cancer Center

Prof Thomas J. Glynn, PhD

Adjunct Lecturer

Stanford Prevention Research Centre, Stanford University School of Medicine

Pamela Kaufman

Morgan Stanley

Prof David Levy

Professor of Oncology

Lombardl Comprehensive Cancer Center, Georgetown University

Professor Ann McNeill

Professor of Tobacco Addiction

UK Centre for Tobacco and Alcohol Studies (UKCTAS), Kings College London

Prof Richard Miech

Principal Investigator, Monitoring the Future

Institute for Social Research, Universithy of Michigan

Stephanie Miller


Sandhill Strategy

Prof Neal L. Benowitz

Professor of Medicine and Bioengineering & Theapeutic Sciences

University of California, San Franciso

Dr Ray Niaura

Director for Science

Schroeder Institute at Truth Initiative

Ass’t Prof Jennifer Pearson

Assistant Professor

University of Nevado, Reno

Dr. Nancy A. Rigotti, MD

Professor of Medicine, Harvard Medical School

Director, Tobacco Research & Treatment Center, Massachusetts General Hospital, Boston

Prof Steven A. Schroeder MD

Distinguished Professor of Health and Healthcare

University of California, San Francisco & Director, Smoking Cessation Leadership Center

Jim Solyst

Consultant to Swedish Match

JMS Scientific Engagement

Prof Andrea Villanti

Associate Professor of Psychiatry and Psychology

Vermont Center on Behavior & Health, at the University of Vermont

Prof Kenneth Warner

Professor Emeritus and Dean Emeritus

School of Public Health, University of Michigan